Abstract
A series of porphyrazines (Pzs) with chiral bis-acetal moieties in the β-pyrrole positions ((2R,3R)-2,3-dimethyl-2,3-dimethoxy-1,4-diox-2-ene) have been synthesized and screened as antitumor agents in MDA-MB-231 breast tumor cells in vitro. The lead Pz 285 was further tested in a mouse tumor xenograft model with Td-tomato-luc2 fluorescent breast tumor cells (MDA-MB-231 LM24 Her2+) that are highly metastatic to the lungs. Pz 285 shows marked antitumor effects in vivo, with treated mice exhibiting longer median survival that we attribute to smaller primary tumor regrowth after resection and less occurrence of metastasis when compared to vehicle control groups. Pz 285 is further compared to the clinically approved chemotherapeutic doxorubicin (Dox). This report lays the groundwork for development of an understudied class of compounds for classical chemotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 705-709 |
Number of pages | 5 |
Journal | ACS Medicinal Chemistry Letters |
Volume | 8 |
Issue number | 7 |
DOIs | |
State | Published - Jul 13 2017 |
Funding
This work was supported in part by Baxter Healthcare Corporation through the Baxter/Northwestern Alliance (to B.M.H.), the Michigan Space Grant Consortium Research Seed Grant (to E.R.T.), and the Oakland University Office of the Provost and Vice President for Academic Affairs (to K.J.M). Animal models were set up in the Tumor Biology Core of Northwestern University, which benefits from philanthropic support of the Robert H. Lurie Cancer Center and the Chemistry of Life Processes Institute. Animal studies were approved by the Institutional Animal Care and Use Committee at Northwestern University. Imaging was performed at the Northwestern University Center for Advanced Molecular Imaging generously supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center.
Keywords
- MDA-MB-231 LM24 Her2+
- Porphyrazine
- antitumor
ASJC Scopus subject areas
- Biochemistry
- Drug Discovery
- Organic Chemistry